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2. Abstract 25 
 26 
The metabolic syndrome is a growing epidemic; it increases the risk for diabetes, 27 
cardiovascular disease, fatty liver and several cancers. Several reports have indicated a link 28 
between hormonal imbalances and insulin resistance or obesity. Transgenic (TG) female 29 
mice overexpressing the human chorionic gonadotropin β-subunit (hCGβ+ mice) exhibit 30 
constitutively elevated levels of hCG, increased production of testosterone, progesterone 31 
and prolactin, and obesity. The objective of this study was to investigate the influence of 32 
hCG hypersecretion on possible alterations in the glucose and lipid metabolism of adult TG 33 
females. We evaluated fasting serum insulin, glucose and triglyceride levels in adult 34 
hCGβ+ females and conducted intraperitoneal glucose and insulin tolerance tests at 35 
different ages. TG female mice showed hyperinsulinemia, hypertriglyceridemia and 36 
dyslipidemia, as well as glucose intolerance and insulin resistance at 6 months of age. A 37 
one-week treatment with the dopamine agonist cabergoline applied on 5-week-old hCGβ+ 38 
mice, which corrected hyperprolactinemia, hyperandrogenism, and hyperprogesteronemia, 39 
effectively prevented the metabolic alterations. These data indicate a key role of the 40 
hyperprolactinemia-induced gonadal dysfunction in the metabolic disturbances of hCGβ+ 41 
female mice. The findings prompt further studies on the involvement of gonadotropins and 42 
prolactin on metabolic disorders and might pave the way for the development of new 43 
therapeutic strategies. 44 
 45 
Key words: human chorionic gonadotropin, insulin resistance, transgenic mice, prolactin 46 
 47 
 48 
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3. Introduction 49 
 50 
Metabolic syndrome is a growing epidemic worldwide that involves 1 out of 4 adult 51 
people, and its prevalence increases with age (Grundy, 2008). The consensus statement 52 
provided by the International Diabetes Federation (IDF) defines the metabolic syndrome as 53 
a condition with abdominal obesity plus any two of the following: elevated plasma 54 
triglyceride levels, reduced high-density lipoproteins (HDL), increased blood pressure, or 55 
increased fasting plasma glucose (Alberti et al., 2006). Obesity-associated insulin resistance 56 
is considered a cause-and-effect relationship since weight changes correlate with changes in 57 
insulin sensitivity (Kahn et al., 2006, Qatanani and Lazar, 2007). In this respect, 58 
hyperlipidemia is linked to insulin resistance, since insulin promotes fat cell differentiation, 59 
enhances adipocyte glucose uptake, and inhibits adipocyte lipolysis.  60 
Although the role of prolactin in reproduction is well known, the participation of 61 
this hormone in weight gain and glucose homeostasis is still under debate. Patients with 62 
prolactinomas were reported to acquire weight gain and metabolic alterations (Greenman et 63 
al., 1998; Ben-Jonathan et al., 2008). However, it is still unclear whether these conditions 64 
are directly associated to hyperprolactinemia (Ciresi et al., 2013). Recent experimental 65 
evidence suggests that prolactin has a crucial role on the pancreas and the adipose tissue, 66 
most notably during development. Prolactin receptor deficient mice (Prlr-/-) provided 67 
direct evidence that prolactin signaling is involved in adipogenesis by affecting energy 68 
balance and metabolic adaptation (Carre and Binart, 2014). Furthermore, prolactin is shown 69 
to be essential for the pancreatic β-cell development during the perinatal period (Auffret et 70 
al., 2013), and is therefore, involved in the manifestation of insulin resistance by 71 
stimulating insulin release and regulating adipokine release (Ben-Jonathan et al., 2008; 72 
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Carre and Binart, 2014). Prolactin was found to decrease glucose transporter 4 (GLUT 4) 73 
mRNA expression that may cause a decreased glucose uptake in peripheral tissues (Nilsson 74 
et al., 2009). Moreover, prolactin induces pyruvate dehydrogenase kinase 4 (PDK4), whose 75 
activation is known to lead to decreased glucose oxidation (White et al., 2007).  In addition, 76 
this hormone participates in perinatal brown adipocyte differentiation and function 77 
(Viengchareum et al., 2008), and also affects energy homeostasis through modulation of 78 
lipid metabolism (Carre and Binart, 2014).  79 
We have previously shown the implications of chronically elevated levels of hCG in 80 
the phenotype of transgenic (TG) mice. Particularly, female mice overexpressing the 81 
hCGβ- subunit (hCGβ+) exhibit precocious puberty, elevated serum levels of hCG, 82 
prolactin, testosterone and progesterone, and present with infertility (Rulli et al., 2002; 83 
Ratner et al., 2012). Besides, hCGβ+ ovaries show hemorrhagic cysts and massive 84 
luteinization as a result of the active stimulation with hCG (Rulli et al., 2002; Ratner et al., 85 
2012). Among the extragonadal phenotypes, these females develop obesity, pituitary 86 
macroprolactinomas, mammary gland tumors and elevated bone density at older ages (Rulli 87 
et al., 2002; Yarram et al., 2003; Kuorelahti et al., 2007; Ahtiainen et al., 2010; Ratner et 88 
al., 2012). In contrast to transgenic females, hCGβ+ males are fertile and exhibit normal 89 
levels of testosterone and prolactin (Rulli et al., 2003).  90 
Even though LH/hCG receptors are detected in different non-gonadal tissues, 91 
including the pancreas (Abdallah et al., 2004; Cole, 2010), their physiological significance 92 
remains unclear. Our previous studies demonstrate that hyperprolactinemia is the main 93 
cause for the reproductive defects of adult hCGβ+ females, which can be prevented by a 94 
short-term treatment with the dopamine agonist cabergoline at the beginning of the 95 
reproductive age (Ratner et al., 2012). Conversely, the same treatment applied at 3 months 96 
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of age failed to recover fertility. These findings demonstrate that the cabergoline treatment 97 
applied at a critical moment of the phenotype progression prevents hCG-induced 98 
abnormalities in these transgenic mice.  99 
The aim of this study was to investigate the possible alterations of glucose and lipid 100 
metabolism in adult hCGβ+ females. The short-term treatment with cabergoline was 101 
followed in order to assess whether hyperprolactinemia influenced metabolism in the 102 
hypersecreting hCGβ females. Since hCGβ+ males do not exhibit changes in prolactin 103 
levels, this study was focused on females. Glucose and insulin tolerance tests were 104 
conducted at different ages, as well as determination of serum insulin concentration and 105 
pancreatic gene expression analysis. Since obesity was described as part of the extra-106 
gonadal phenotype, serum triglycerides, cholesterol and high density lipoprotein cholesterol 107 
(HDL-C) were also measured in TG females.  108 
 109 
4. Materials and Methods 110 
 111 
Animals 112 
 All the experiments were performed in TG female mice overexpressing the hCGβ- 113 
subunit under the control of the human ubiquitin C promoter (hCGβ+). Generation, housing 114 
and genotyping of hCGβ+ with FVB/N genetic background have been previously described 115 
(Rulli et al., 2002).  Wild-type (WT) littermates were used as controls. Mice were 116 
maintained under controlled conditions (12-h light/dark cycle, 21 C), and were given free 117 
access to laboratory chow and tap water. Food intake was monitored daily on females 118 
caged individually during one week. All experimental procedures were performed 119 
according to the NIH Guidelines for Care and Use of Experimental Animals, and approved 120 
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by the Institutional Animal Care and Use Committee of the Instituto de Biología y 121 
Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas 122 
(IBYME-CONICET).  123 
 124 
Cabergoline treatment  125 
 WT and hCGβ+ female mice of 5 weeks of age were injected ip with 500 µg/kg of 126 
cabergoline (Laboratorios Beta S.A., Buenos Aires, Argentina) suspended in 0.25% (w/v) 127 
methylcellulose as vehicle (Tanaka and Ogawa, 2005). The females received three 128 
injections of cabergoline, one every other day, during 1 week (hCGβ+cab) (Ratner et al., 129 
2012). The females used as controls were injected with vehicle only.  130 
 131 
Glucose homeostasis tests  132 
 Two, three and 6-month-old female mice were fasted for 6 or 3 hr and blood was 133 
collected from the tail vein, to perform glucose tolerance test (IGTT) or insulin tolerance 134 
test (ITT) respectively. Glucose (2 g/kg, dissolved in water) or insulin (0,75 IU/kg Humulin 135 
R, Eli Lilly Interamericana, Argentina) was administered by i.p. injection. Blood glucose 136 
was determined at time points 0, 30, 60 and 90 min according to manufacturer´s 137 
recommendations by using a glucometer Accu-Chek (Roche) (Andrikopoulos et al., 138 
2008).The ITT was performed on the same group of animals one week after IGTT. In 139 
addition, glucose-stimulated insulin secretion was determined from serum samples of 6-140 
hour-fasted females of 3 and 6 months of age, at 0 and 30 min after glucose administration. 141 
Serum samples were obtained by centrifugation and stored at -20 C. Insulin levels were 142 
assessed by rat/mouse insulin Elisa kit (EZRMI-13K; Millipore). 143 
 144 
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Sample collection 145 
Mice were weighed and euthanized by CO2 asphyxiation at 6 months of age after 18 146 
hr fasting, and cardiac blood was obtained immediately thereafter. Serum samples were 147 
separated by centrifugation and stored at -20 C for biochemical analyses. Pancreata were 148 
perfused with RNAlater (Ambion) immediately after dissection, and then snap frozen and 149 
stored at -70 C for RNA isolation. 150 
 151 
Biochemical analyses 152 
Serum cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) 153 
concentrations were measured by colorimetric assays (BioSystems, Spain) according to the 154 
manufacturer’s instructions. Serum lipid indices were calculated according to the following 155 
formulas: Cholesterol / HDL-C (Castelli, 1996); Triglycerides / HDL-C (McLaughlin et al., 156 
2003). The calculation of HOMA-IR (Homeostasis Model Assessment Insulin Resistance) 157 
was performed according to the formula of Matthews et al. (1985): (Glucose mmol / dl x 158 
Insulin mUI / ml) / 22.5. The Quicki (Quantitative Insulin Sensitivity Check Index) was 159 
calculated consistent with Katz et al. (2000): 1 / (Log Insulin mUI / ml + Log Glucose mg / 160 
dl). 161 
 162 
hCG bioassay 163 
The bioactive levels of circulating hCG were determined by the mouse testicular 164 
interstitial cell in vitro bioassay as previously described (Ding and Huhtaniemi, 1989; Rulli 165 
et al, 2002). Briefly, decapsulated testes from adult WT males were dispersed with 166 
collagenase type I (0.15 mg/ml) in M199 medium (Sigma-Adrich) for 5 min at 34 C. The 167 
supernatant was filtered through nylon mesh (mesh size 100 µm) and the cell suspension 168 
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was washed twice with M199 medium supplemented with 0.1% (w/v) bovine serum 169 
albumin (BSA; Sigma-Aldrich) and 20mM HEPES (Sigma-Aldrich). Testicular interstitial 170 
cells obtained using this technique are predominantly Leydig cells, as described previously 171 
(Ding and Huhtaniemi, 1989). Cells (50 000 cells/tube) were incubated with increasing 172 
concentrations of recombinant hCG as standard (AFP8456A, 20000 IU/mg; NHPP, 173 
NIDDK), or with the serum samples, in a 95%O2/5%CO2 atmosphere at 34 C for 4 h. After 174 
incubation, supernatants were recovered by centrifugation and frozen at -20 C. The 175 
testosterone concentration in the supernatants was measured by radioimmunoassay, 176 
according to a method described previously (Ratner et al., 2012). The intra- and inter-assay 177 
coefficients of variation were less than 12%. 178 
 179 
In vivo peripheral tissue response to insulin 180 
Six-month-old WT and hCGβ+ female mice were fasted for 4 h. Then, animals were 181 
anesthetized with 2% avertin (12 ml/kg i.p.). The abdominal cavity was opened and 2 IU/kg 182 
of insulin was injected into the portal vein. At time points 0 and 5 min post-injection, 183 
portions of skeletal muscle were excised and flash frozen in liquid N2 and stored at −70 C 184 
until used.  185 
 186 
Western blot analysis 187 
Skeletal muscle homogenates were prepared with lysis buffer (50 mM TRIS, 150 188 
mM NaCl2, 1mM EDTA, 0.1%SDS, 0.5% sodium deoxycholate, 1% NP40-IGEPAL), 200 189 
mM sodium orthovanadate (NO3VO4), 200mM NaF and protease inhibitor cocktail  190 
(Roche). Concentration was determined by the method of Lowry (1951), using BSA as 191 
standard protein. Fifteen µg of protein from each sample was resolved by 10% SDS-PAGE 192 
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under reducing conditions and transferred to nitrocellulose membranes (Amersham 193 
Hybond-ECL, GE Healthcare Life Sciences, Pittsburgh, PA, USA). To reduce non-specific 194 
antibody binding, membranes were incubated for 1 h at room temperature in T-TBS 195 
blocking buffer. The membranes were then incubated overnight at 4 C with antibodies anti-196 
AKT and anti-pAKT in T-TBS, 1% BSA (Cell Signalling, MA; AKT, #9272S:1/500; 197 
pAKT, #4060S: 1/2000). Secondary goat anti-rabbit antibody conjugated with peroxidase 198 
HRP (Santa Cruz Biotechnology inc, CA, # sc-2004: 1/5000) were used. For actin 199 
detection, membranes were incubated overnight at 4 C with first antibody diluted in PBS-T, 200 
1% BSA (Calbiochem CA, # cp01: 1:5000) followed by incubation with secondary goat 201 
anti-mouse IgM antibody conjugated with peroxidase HPR (Santa Cruz Biotechnology Inc, 202 
CA, # sc-2064:1/2000). Immunoreactive proteins were revealed by enhanced 203 
chemiluminescence (ECL-Plus, Amersham, GE Healthcare LifeSciences) using hyperfilm 204 
ECL (GE Healthcare LifeSciences) and band intensities were quantified using Scion 205 
Analyzer software. 206 
 207 
Immunohistochemistry  208 
 Pancreata from 6-month-old WT, hCGβ+ and hCGβ+cab female mice were fixed in 209 
4% paraformaldehyde, dehydrated and embedded in paraffin wax. Endogenous peroxidase 210 
reactivity was quenched by a 20-min pretreatment with 10% methanol, 0.3% H2O2 in 211 
0.01 M PBS (pH 7.4). For antigenic retrieval, sections were pretreated with citrate buffer 212 
(0.01M, pH 6), and permeabilized by a 5-min incubation with 0.5% saponin in PBS and 5-213 
min incubation with proteinase K (10 ng/ml). Non-specific proteins were blocked by 214 
subsequent incubation with protein blocking buffer (5% goat normal serum in PBS for 215 
Pdx1, and 5% horse normal serum in PBS for Nkx 6.1) for 30 min. After several wash 216 
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steps, sections were incubated with antibodies rabbit anti-Pdx1 (Millipore, CA, # 06-1379: 217 
1/1000) and mouse anti-Nkx 6.1 (DSHB, # F55A10-S: 1/250) diluted in incubation buffer 218 
(2% goat normal serum in PBS for Pdx1; 2% horse normal serum in PBS for Nkx 6.1) 219 
overnight in a humidified chamber at 4 C. On the second day, pancreata sections were 220 
washed and incubated with biotinylated secondary antiserum (goat anti-rabbit IgG; horse 221 
anti-mouse IgG, 1:500, Vector Lab., CA, USA) for 2 h at room temperature. Finally, 222 
immunoreaction was visualized with 0.01% H2O2 and 0.05% 3,3-diaminobenzidine 223 
solution (in 0.05  M Tris–HCl, pH 7.6) and an avidin–biotin–peroxidase system (Vector 224 
Lab). Negative controls were performed in the absence of the primary antibodies. 225 
 226 
RNA isolation and analysis of gene expression  227 
Total RNA was isolated from pancreata as previously described (Gonzalez et al., 228 
2011), using TRIZOL reagent (Invitrogen) according to the manufacturer’s protocol. Two 229 
micrograms of RNA were treated with DNAse I (Invitrogen) and reverse-transcribed in a 230 
20 µl reaction volume using M-MLV reverse transcriptase (Promega) and random 231 
hexameres (Biodynamics). For quantitative real-time PCR (qPCR) primer sets were 232 
designed for the specific amplification of Ins1, Ins2, Gcg (Ins1 Fw: 233 
AAGCTGGTGGGCATCCAGTAACC, Ins1 Rev: GTTTGGGCTCCCAGAGGGCAAG; 234 
Ins2 Fw: CCCTGCTGGCCCTGCTCTT, Ins2 Rev: AGGTCTGAAGGTCACCTGCT; Gcg 235 
Fw: CTACACCTGTTCGCAGCTCA, Gcg Rev: CTGGGGTTCTCCTCTGTGTC), and 236 
cyclophilin A (Ppia) as an internal control (Ppia Fw: GCGTCTCCTTCGAGCTGTT, Ppia 237 
Rev: AAGTCACCACCCTGGCAC). Each sample was assayed in duplicate using 4 pmol 238 
of each primer, SYBR Green Master Mix (Applied Biosystems) and 2-20ng of cDNA in a 239 
total volume of 15 µl. Amplification was carried out in a CFX96 Touch™ Real-Time PCR 240 
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Detection System (Bio-Rad). For the assessment of quantitative differences in the cDNA 241 
target between samples the mathematical model of Pfaffl (2001) was applied. An 242 
expression ratio was determined for each sample by calculating (Etarget)
∆Ct
 
(target)
/(EPpia)
∆Ct
 243 
(Ppia)
, where E is the efficiency of the primer set and ∆Ct= Ct (reference cDNA) – Ct 244 
(experimental cDNA). The amplification efficiency of each primer set was calculated from 245 
the slope of a standard amplification curve of log (nanograms of cDNA) per reaction vs. Ct 246 
value (E = 10
-(1/slope)
). Efficiencies of 2±0.1 were considered optimal. Results were 247 
expressed relative to a reference sample (WT choosen ad random). 248 
 249 
Statistical Analysis 250 
Data are expressed as the mean ± SEM. Statistical analysis for comparing two sets 251 
of data was performed with Student’s t test for two independent groups. In those 252 
experiments where the effects of two factors (genotype and treatment) were studied, the 253 
two-way ANOVA was performed. The two-way ANOVA with repeated measures was used 254 
for the glucose and insulin tolerance tests. Bonferroni’s post-hoc test was used to establish 255 
the level of significance between group pairs. The trapezoidal rule was used to determine 256 
the area under the curve (AUC). Data were transformed when required. A p value less than 257 
0.05 was considered significant.  258 
 259 
5. Results  260 
Hormonal and metabolic status of hCGβ+ female mice 261 
 We have previously demonstrated that at 6 months of age, hCGβ+ female mice 262 
showed pronounced disturbances in their gonadal and non gonadal phenotype (Rulli et al., 263 
2002; Ratner et al., 2012). As was confirmed in Table 1, hCGβ+ females exhibited a 264 
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significant increase in body weight, abdominal white fat depot and serum levels of 265 
bioactive hCG as compared with WT (p<0.01) (Rulli et al., 2002; Ratner et al., 2012). This 266 
change, however, was not accompanied by an increase in the daily food intake. At this age, 267 
serum levels of insulin and triglycerides were elevated in TG females (p<0.001). On the 268 
other hand, serum fasting glucose, cholesterol and HDL-C levels did not show differences 269 
between WT and hCGβ+ females (Table 1). In addition, the atherogenic (or Castelli) index, 270 
represented by the ratio of cholesterol/HDL-C, did not show significant differences 271 
between the groups, whereas the triglycerides/HDL-C ratio showed a statistically 272 
significant increase in hCGβ+ females as compared with WT females (p < 0.001). From 273 
fasting insulin and glucose data, we calculated the surrogate indexes of insulin sensitivity 274 
and resistance HOMA-IR and QUICKI. The values of HOMA-IR were significantly higher 275 
in the hCGβ+ group compared with WT (p<0.05; Table 1), as observed for groups of mice 276 
with decreased insulin sensitivity. Conversely, the value of QUICKI was significantly 277 
lower in the hCGβ+ group compared with WT (p<0.05), also indicative of diminished 278 
insulin sensitivity. 279 
 280 
Age-dependent changes in the glucose homeostasis of hCGβ+ females 281 
In order to study a possible correlation with age, IGTT and ITT were performed in 282 
2, 3 and 6-month-old WT and hCGβ+ females. No differences were found in IGTT at two 283 
months of age (Fig. 1 A). At 3 and 6 months of age, TG females showed glucose 284 
intolerance, represented by a delay in glucose clearance and an increase in glucose levels 285 
through the different time-points analyzed after glucose administration (Fig. 1 B,C).  286 
Accordingly, the total glucose levels accumulated during the 90 min of the assay, 287 
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represented as the AUC, were significantly increased in hCGβ+ females as compared with 288 
WT (p<0.01).  289 
 The ITT performed in 2 and 3 month-old TG females showed a quick decline in 290 
glucose levels at 30 min after insulin administration, and remained low thereafter, as it was 291 
observed in WT females at the same ages (Fig. 2 A,B). However, 6-month-old hCGβ+ 292 
females showed elevated glucose levels after insulin administration, which remained high 293 
through the different time-points analyzed (Fig. 2 C). Accordingly, the AUC resulted 294 
elevated in hCGβ+ females (p<0.01).  295 
The insulin secretion capacity in response to glucose administration was performed 296 
in 3- and 6-month-old WT and hCGβ+ females (Fig. 3A). The glucose response was first 297 
measured at 30 min, meaning that only the second phase of insulin secretion was detected 298 
in this study (Caumo and Luzi, 2004). TG mice from both ages exhibited elevated basal 299 
insulin levels as compared with WT females. The insulin secretion of WT females from 300 
both ages showed a correct response to glucose stimulation with at least a 2.5- fold increase 301 
at 30 min post-glucose administration (p<0.05). Conversely, 3- and 6-month-old hCGβ+ 302 
mice exhibited an impaired glucose- stimulated response, being only a 0.8 and 1- fold 303 
increase, respectively (Fig. 3A).  304 
 Since TG female mice showed profound alterations in glucose metabolism at 6 305 
months of age, we further analyzed the peripheral insulin sensitivity at this age. To this aim, 306 
we determined the status of insulin- induced AKT phosphorylation in skeletal muscle 307 
obtained from fasted WT and hCGβ+ mice (Fig 3B). As expected, WT females showed a 3-308 
fold increase in insulin-stimulated AKT phosphorylation (p<0.05), whereas TG females 309 
exhibited a severely impaired AKT activation, with levels comparable to basal of both 310 
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groups (p<0.05). TG females showed an increase in total AKT as compared with WT 311 
(p<0.05). 312 
Taken together these results showed that 6-month-old hCGβ+ females exhibited 313 
peripheral insulin resistance and impaired glucose tolerance, being the most important 314 
disruptions in glucose homeostasis. 315 
 316 
Effect of cabergoline on the glucose and lipid homeostasis of hCGβ+ females. 317 
Treatment with the dopaminergic agonist cabergoline was carried out to analyze the 318 
influence of hyperprolactinemia on serum insulin, glucose and triglycerides. It was 319 
confirmed that a short-term treatment with cabergoline administered at 5 weeks of age to 320 
hCGβ+ females (hCGβ+cab) was effective in the normalization of prolactin levels 321 
(p<0.001; Fig 4B) and body weight (p<0.05; Fig 4 A) at 6 months of age (Ratner et al., 322 
2012).  In addition, cabergoline treatment restored serum triglycerides (p<0.001; Fig. 4 D) 323 
and insulin (p<0.05; Fig. 4 C) to normal levels in comparison to hCGβ+ control females. 324 
Cabergoline treatment administered to 5-week-old WT females (WTcab), did not produce 325 
any effect on the parameters studied (Fig. 4 A-D).    326 
 327 
Effect of cabergoline on IGTT and ITT of hCGβ+ females  328 
 IGTT and ITT were performed to further analyze the influence of prolactin on the 329 
glucose homeostasis of the TG females (Fig. 5). The IGTT showed a similar clearance in 330 
WT and WTcab females, with significantly increased glucose levels of hCGβ+ females at 331 
30, 60 (p<0.001) and 90 (p<0.01) min after glucose administration (Fig. 5 A). hCGβ+ 332 
females treated with cabergoline showed a significant reduction of the glucose levels at 30 333 
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min, as compared with the results obtained for hCGβ+ females. In line with this, the AUC 334 
exhibited similar results (Fig. 5 B).  335 
The ITT demonstrated that cabergoline treatment fully prevented the appearance of 336 
insulin resistance in TG females (Fig. 5 C). This was confirmed by analyzing the AUC: 337 
complete normalization occurred in cabergoline treated TG females with respect to control 338 
hCGβ+ females (p<0.05; Fig. 5 D). 339 
 340 
Effect of cabergoline on pancreatic Ins1, Ins2, Gcg, Pdx1 and Nkx 6.1 in hCGβ+ 341 
females. 342 
Due to the effectiveness of the cabergoline treatment in normalizing the glucose 343 
homeostasis of TG females, we assessed gene expression for preproinsulin (Ins1 and Ins2) 344 
and glucagon (Gcg) in pancreatic tissue of 6-month-old hCGβ+ and hCGβ+cab females. In 345 
agreement with the increased serum levels of insulin, hCGβ+ females exhibited 346 
significantly increased gene expression of both Ins1 and Ins2, as compared with WT 347 
females (p<0.05, Fig 6A). The cabergoline treatment restored the expression levels of the 348 
genes for insulin to the level obtained in WT mice (Fig. 6 A). In contrast, the expression of 349 
Gcg did not show significant differences among the groups studied (Fig. 6A). The 350 
cabergoline treatment applied to WT females did not affect the expression levels of the 351 
genes analyzed. 352 
In addition, we performed immunohistochemistry for two well known markers of β-353 
cell maturity and identity, PDX1 and NKX 6.1. The presence of both markers was detected 354 
in the pancreatic islets of WT, hCGβ+ and hCGβ+cab, and the expected nuclear 355 
localization was observed (Fig 6B). 356 
 357 
Page 15 of 39
16 
 
6. Discussion  358 
The influence of hormones on glucose and lipid metabolism may be evidenced, 359 
among others, in various clinical conditions such as hormone replacement therapy, 360 
pregnancy, menopause, and hyperandrogenic states. Several models have been useful for 361 
understanding the pathophysiology of the metabolic syndrome (Kennedy et al., 2010; Guo, 362 
2014). We report here a TG mouse model that shows a clear link between alterations of the 363 
gonadotropin axis and metabolic dysfunctions.  364 
As previously demonstrated, hCGβ+ females exhibit elevated levels of hCG, 365 
progesterone, testosterone and prolactin, precocious puberty associated with a transient 366 
increase of serum estradiol, and infertility at adulthood (Rulli et al., 2002; Ratner et al., 367 
2012). Besides, hCGβ+ females show obesity, mainly with abdominal fat accumulation, 368 
macroprolactinomas, mammary adenocarcinoma and increased bone mineral density at 369 
older ages (Rulli et al., 2002; Yarram et al., 2003; Ahtiainen et al., 2010; Kuorelahti et al., 370 
2010; Bachelot et al., 2013). These extra-gonadal phenotypes of the hCGβ+ females are 371 
abolished by gonadectomy, indicating that ovarian hCG hyperstimulation with abnormal 372 
gonadal hormone production is directly or indirectly responsible for the extra-gonadal 373 
phenotype observed in this model (Rulli et al., 2002). Furthermore, we have shown that a 374 
short-term treatment with the dopamine agonist cabergoline to hCGβ+ females abolishes 375 
hyperprolactinemia, normalizes steroid hormone levels, and prevents the development of 376 
mammary tumors and pituitary adenomas in adulthood, thus, demonstrating the pivotal role 377 
of prolactin on certain phenotypic alterations of hCGβ+ females (Ratner et al., 2012). In the 378 
present study, we showed that the endocrinological alterations induced by chronic hCG 379 
overproduction lead to significant metabolic dysfunctions associated with 380 
hyperinsulinemia, glucose intolerance and impaired glucose- stimulated insulin secretion 381 
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that precedes/accompanies the development of insulin resistance. The failure of β-cell 382 
function in this model is evident, since despite hyperinsulinemia, basal glucose ranged 383 
within the normal values, but not after an i.p. glucose load. Besides, hypertriglyceridemia 384 
and high triglyceride/HDL-C index were found in adult female mice. 385 
It is well known that AKT activation is involved in insulin sensitivity in peripheral 386 
organs. Specifically, in the skeletal muscle insulin activates, via IRS-1, the signalling 387 
pathways that involve phosphatidylinositol (PI) 3-kinase and its downstream effector AKT, 388 
which mediates glucose uptake by leading to membrane translocation of GLUT 4 389 
(Bjornholm et al., 1997). Given the evidence of insulin resistance and hyperinsulinemia 390 
with normoglycemia in TG females, we analyzed the activation of akt in skeletal muscle. It 391 
seems that two phenomena coexist in this model. Firstly, high basal AKT expression with 392 
the consequent increase in basal AKT phosphorylation, and secondly the impaired AKT 393 
activation after insulin stimulation. A similar situation was found in a mouse model under 394 
high fat diet (Liu et al., 2009). These animals also showed insulin resistance and 395 
hyperinsulinemia with normoglycemia. Moreover, basal AKT phosphorylation was 396 
increased, thus showing an adaptation of the system to the high insulin levels, and allowing 397 
the maintenance of glucose levels within the normal range (Liu et al., 2009). In the same 398 
way, we found an increase in basal AKT phosphorylation that would explain the 399 
normoglycemia observed. These findings, together with the inability to respond to 400 
exogenous insulin stimulation, suggest that the high AKT protein levels would lead to a 401 
saturation of the AKT kinase activity, thus producing a decrease in the rate of insulin-402 
stimulated phosphorylation and explaining the insulin resistance observed in our model. 403 
Similar results were observed in humans, with altered AKT activation in skeletal muscle 404 
under hyperinsulinemic conditions (Karlsson et al., 2005). In addition, the db/db mice 405 
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model, as well as obese diabetic human patients, also exhibit decreased AKT 406 
phosphorylation but unaltered basal total AKT in skeletal muscle (Shao et al., 2000; 407 
Gosmarov et al., 2004).   408 
The role of prolactin on reproduction has been extensively studied, but implications 409 
of this hormone on metabolism, body weight and energy regulations are an open issue. 410 
Pregnant and lactating women exhibit hypoadiponectinemia due to prolactin influence on 411 
secretion and expression of adiponectin (Asai-Sato et al., 2006). In hamsters, inhibition of 412 
prolactin secretion by bromocriptine has led to a reduction in fat depots, without reducing 413 
food intake or body weight (Freeman et al., 2000). It has been reported that prolactin is 414 
involved in adipose tissue differentiation as well as regulation of energy expenditure 415 
(Auffret et al., 2012). The absence of prolactin receptor in Prlr KO mice prevents high-fat 416 
diet-induced weight gain, despite increased food intake through an increase in energy 417 
expenditure and metabolic rate. In an opposite way, in our model, hyperprolactinemia 418 
would be one of the main effectors on the weight gain by inducing accumulation of white 419 
abdominal fat depot and decreasing energy expenditure, with no change in food intake.  420 
The lactogenic hormones during pregnancy enhance insulin production in response 421 
to the growing metabolic demands on the mother and affect pancreatic islet development in 422 
the fetus (Ben-Jonathan et al., 2008). Interestingly, the hyperprolactinemic state due to a 423 
selective disruption of the dopamine D2 receptor in the lactotropes of female mice 424 
(lacDrd2KO) leads to increased body weight, triglycerides, and glucose intolerance, but the 425 
response to insulin was preserved (Perez Millan et al., 2014). The short-term treatment with 426 
cabergoline provoked a recovery of glucose tolerance and a complete reversal of the insulin 427 
resistance, as well as a significant reduction in insulin and triglyceride levels. In this regard, 428 
cabergoline effectively prevented the hyperprolactinemia-associated metabolic 429 
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dysfunctions in TG mice. These findings provide strong evidence that elevated prolactin 430 
has a key role for the metabolic alterations in hCG overproducing females by acting 431 
directly on the target organs, and indirectly via alteration of the steroid hormone 432 
production. This could be explained by the persistent stimulus of prolactin together with 433 
hCG. This induces a significant increase of ovarian Lhcgr accompanied by a massive 434 
ovarian luteinization, which results in elevated levels of progesterone and testosterone 435 
(Ratner et al., 2012).  436 
Androgens affect lipid metabolism by increasing the activity of lipoprotein lipase 437 
and hepatic lipase, by causing an increase in triglycerides, LDL-C and decrease the levels 438 
of HDL-C (LaRosa, 1995). Estrogens, on the contrary, increase HDL-C and decrease LDL-439 
C levels (Gillmer, 1992; Tikkanen, 1996). The influence of androgens on lipid metabolism 440 
was also demonstrated in female rats under prenatal androgen treatment, which developed 441 
dyslipidemia and hepatic steatosis in adulthood. These changes would be the consequence 442 
of increased adipose tissue and insulin resistance induced by prenatal androgenization 443 
(Demissie et al., 2008). A similar metabolic alteration has been described in adult rats 444 
following early postnatal administration of testosterone (Alexanderson et al., 2007). 445 
Exposure to high levels of gonadal steroids, especially testosterone and progesterone 446 
throughout life (Rulli et al., 2002), could be one of the predisposing factors for 447 
dyslipidemia in this TG model, which is reinforced by the presence of obesity and insulin 448 
resistance. 449 
The characteristic hyperprolactinemia in hCGβ+ females is a possible player in the 450 
adaptation of the pancreas to an increased insulin demand. Some lines of evidence serve as 451 
support for this purpose, as activation of prolactin receptor in the pancreas may be 452 
responsible for the increase in islet β-cells during pregnancy (Ben-Jonathan, 2008; Huang 453 
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et al., 2009; Huang, 2013). In vitro exposure of islets to prolactin increases insulin 454 
secretion, β-cell proliferation and decreases the threshold of insulin response to glucose 455 
(Huang et al., 2009). On the other hand Prlr KO mice showed islet and β-cell hypoplasia, 456 
reduced pancreatic insulin mRNA levels, a blunted insulin secretory response to glucose, 457 
and mild glucose intolerance (Freemark et al., 2001). During pregnancy of heterozygous 458 
Prlr +/- mice, pancreatic islet adaptation to blood glucose and the functioning mass of 459 
β−cell is affected (Huang et al., 2009).  460 
Sex hormones collectively have the ability to reduce the sensitivity to insulin. It is 461 
known that estrogen and progesterone increase the pancreatic secretion of insulin and 462 
induce insulin resistance (Garcia et al., 1983; Gonzalez et al., 2000; Livingstone and 463 
Collison, 2002). These behave as counterregulatory hormones of glucose homeostasis 464 
during the early stages of pregnancy, and as a result, β-cell hyperplasia and increased 465 
pancreatic insulin secretion is observed (Macotela et al., 2009). 466 
Rats and mice have two structurally similar insulin genes, Ins1 and Ins2. Both genes 467 
are functional but there is no consensus about their relative expression in rodent β-cells 468 
(Roderigo-Milne et al., 2002). Changes in glucose metabolism of hCGβ+ females were 469 
accompanied by a significant increase in the expression of both genes. This confirmed that 470 
hyperinsulinemia resulted from the overproduction of insulin in pancreatic β-cells of the 471 
hCGβ+ females. The identity of insulin- producing pancreatic β cells was confirmed by the 472 
visualization of the specific markers PDX1 and NKX 6.1 in hCGβ+ mice. Besides, 473 
cabergoline treatment was able to significantly reduce the Ins1 and Ins2 mRNA levels, in 474 
concordance with the normalization of serum insulin in transgenic females.  475 
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In light of Metabolic Syndrome as a growing epidemic, animal models are good 476 
tools to determine the pathophysiological basis of this disease and how increases the risk 477 
for other diseases. This transgenic model overexpressing hCG gives us the possibility to 478 
study the consequences of hormone alterations in metabolic dysfunctions. 479 
Hyperprolactinemia associated with an altered gonadal function would explain the altered 480 
lipid and glucose metabolism in hCGβ+ female mice, considering that all these changes 481 
were manifested after the occurrence of high levels of gonadal steroids and prolactin, which 482 
started at early age and persisted high throughout life. On the other hand, the presence and 483 
activation of LH/hCG receptors in pancreatic β cells suggests a role for LH/hCG as a 484 
potential regulator of insulin release (Parkash et al., 2015). Consequently, the potential 485 
direct participation of hCG in the metabolic process deserves future studies. 486 
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11. Figure legends 
 
Figure 1. Intraperitoneal Glucose Tolerance Test (IGTT) in hCGβ+ female mice at 2, 3 and 
6 month of age. IGTT (2 g/kg) in fasted WT and hCGβ+ females was performed at 2 (A), 3 
(B) (n=4), and 6 (C) months of age (n=7). Two-way ANOVA with repeated-measures, 
followed by Bonferroni’s post hoc test was conducted; * p<0.05; ** p<0.01; *** p<0.001. 
The area under the curve (AUC) was analyzed for each group at different ages; Student´s t-
test was conducted; ** p<0.01. Data are presented as mean±SEM. 
 
Figure 2. Intraperitoneal Insulin Tolerance Test (ITT) in hCGβ+ female mice at 2, 3 and 6 
month of age. ITT (0.75 IU/kg) in fasted WT and hCGβ+ females was performed at 2 (A), 
3 (B) (n=4) and 6 (C) months of age (n=6). Two-way ANOVA with repeated-measures, 
followed by Bonferroni’s post hoc test was conducted; * p<0.05; *** p<0.001. The area 
under the curve (AUC) was analyzed for each group at different ages; Student´s t-test was 
conducted; ** p<0-01. Data are presented as mean±SEM. 
 
Figure 3. (A) Glucose- stimulated insulin release in 3- and 6-month-old hCGβ+ female 
mice.  Glucose (2 g/kg) was administered i.p. to fasted WT and hCGβ+ female mice, and 
serum insulin levels were measured at 0 and 30 min post-glucose. Two-way ANOVA with 
repeated-measures, followed by Bonferroni’s post hoc test was conducted. Data are 
presented as mean±SEM (n=4). *: P<0.05; **: p<0.01. (B)  Peripheral tissue response to 
insulin. A representative western blot was shown for AKT activation in skeletal muscle. 
Samples were obtained from fasted 6-month-old WT and hCGβ+ female mice at 0 or 5 min 
after insulin administration. Two-way ANOVA followed by Bonferroni’s post hoc test or 
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Student’s t-test was conducted according to each case. Different letters indicate a value of 
at least p<0.05. Data are presented as mean±SEM (n=4). 
 
Figure 4. Effect of cabergoline on body weight and serum levels of prolactin, insulin, and 
triglycerides in hCGβ+ females. Body weight (A) and serum prolactin (B), insulin (C) and 
trygicerides (D) levels in 6-month-old cabergoline- treated transgenic females (hCGβ+cab) 
(n=8) after 18 hr fasting. WT (n=12), cabergoline-treated WT (WTcab) (n=4) and hCGβ+ 
(n=8) females were used as controls. ANOVA, followed by Bonferroni’s post hoc test was 
conducted. Different letters indicate a value of at least p<0.05. Data are presented as 
mean±SEM. 
 
Figure 5. Effect of cabergoline treatment on the glucose homeostasis in WT and hCGβ+ 
females.  IGTT (2 g/kg) (A), and ITT (0.75 IU/kg) (C) in fasted 6-month-old cabergoline- 
treated transgenic (hCGβ+cab) females was performed (n=8); fasted 6-month-old WT 
(n=12), cabergoline-treated WT (WTcab) (n=4) and hCGβ+ females (n=12) were used as 
control groups. Two-way ANOVA with repeated-measures, followed by Bonferroni’s post 
hoc test was conducted. A) WT vs hCGβ+ **: p<0.01; ***: p<0.001; hCGβ+ vs hCGβ+cab 
##: p<0.01; C) hCGβ+ vs WT, WTcab, hCGβ+cab; **: p<0.01, ***: p<0.001. The area 
under the curve (AUC) was analyzed for the different groups (B, D). ANOVA followed by 
Bonferroni’s post hoc test was conducted. Different letters indicate a value of at least 
p<0.05. Data are presented as mean±SEM. 
 
Figure 6. (A) Effect of cabergoline on the pancreatic gene expression of Ins1, Ins2, Gcg and 
Ccnd2. The mRNA expression analysis of Ins1, Ins2 and Gcg from fasted 6-month-old 
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WT, hCGβ+ and cabergoline-treated WT (WTcab) and hCGβ+ (hCGβ+cab) pancreata was 
carried out by qRT-PCR. ANOVA, followed by Bonferroni’s post hoc test, was conducted. 
Different letters indicate a value of at least p< 0.05. Data are presented as mean mean±SEM 
(n=4). (B) immunolocalization of PDX1 and NKX 6.1 in pancreas. Representative sections 
from 6-month-old WT, hCGβ+ and hCGβ+cab female mice were immunostained with 
PDX1 and NKX 6.1 specific antibodies. Scale bar 100 µm. 
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Table 1. Metabolic characterization of 6-month-old WT and hCGβ+ female mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean±SEM, the number of animals used in each determination is 
indicated in brackets. Student´s t-test: * p<0,05; ** p<0,01; *** p<0,001.  
 
 WT hCGβ+ 
Body weight (g) 24,7 ± 0,7 (7) 34,9 ± 2,0*** (7) 
Daily food intake (g/mouse) 4,42±0,20 (7) 4,43±0,27 (7) 
Abdominal white fat (g) 1,79±0,35 (7) 3,72±0,42** (7) 
Bio hCG (IU/L) 1,79 ± 0,15 (4) 23,46 ± 8,66*** (4) 
Glucose (mg/dl) 152±7 (5) 145±10 (7) 
Insulin (ng/ml) 0,21±0,07 (5) 1,07±0,21*** (7) 
HOMA-IR 1,78±0,65 (5) 8,78±2,12** (7) 
QUICKI 0,37±0.02 (5) 0,29±0.01** (7) 
Triglycerides (mg/dl) 147±14 (5) 634±61 *** (5) 
Cholesterol (mg/dl) 130±14 (4) 177±18 (5) 
HDL-C (mg/dl) 82±4 (4) 95±5 (5) 
Cholesterol/HDL ratio 1,59±0,18 (4) 1,86±0,14 (5) 
Triglycerides/HDL ratio 1,78±0,11 (4) 6,79±0,22*** (5) 
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Figure 1. Intraperitoneal Glucose Tolerance Test (IGTT) in hCGβ+ female mice at 2, 3 and 6 month of age. 
IGTT (2 g/kg) in fasted WT and hCGβ+ females was performed at 2 (A), 3 (B) and 6 (C) months of age. 
Two-way ANOVA with repeated-measures, followed by Bonferroni’s post hoc test was conducted; * p<0,05; 
** p<0,01; *** p<0,001. The area under the curve (AUC) was analyzed for each group at different ages; 
Student´s t-test was conducted; ** p<0,01. Data are presented as mean±SEM (n=4-7).  
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Figure 2. Intraperitoneal Insulin Tolerance Test (ITT) in hCGβ+ female mice at 2, 3 and 6 month of age. ITT 
(0,75 IU/kg) in fasted WT and hCGβ+ females was performed at 2 (A), 3 (B) and 6 (C) months of age. Two-
way ANOVA with repeated-measures, followed by Bonferroni’s post hoc test was conducted; * p<0,05; *** 
p<0,001. The area under the curve (AUC) was analyzed for each group at different ages; Student´s t-test 
was conducted; ** p<0,01. Data are presented as mean±SEM (n=4-7).  
165x89mm (300 x 300 DPI)  
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Figure 3. (A) Glucose- stimulated insulin release in 3- and 6-month-old hCGβ+ female mice.  Glucose (2 
g/kg) was administered i.p. to fasted WT and hCGβ+ female mice, and serum insulin levels were measured 
at 0 and 30 min post-glucose. Two-way ANOVA with repeated-measures, followed by Bonferroni’s post hoc 
test was conducted. Data are presented as mean±SEM (n=4). *: P<0.05; **: p<0.01. (B)  Peripheral tissue 
response to insulin. A representative western blot was shown for AKT activation in skeletal muscle. Samples 
were obtained from fasted 6-month-old WT and hCGβ+ female mice at 0 or 5 min after insulin 
administration. Two-way ANOVA followed by Bonferroni’s post hoc test or Student’s t-test was conducted 
according to each case. Different letters indicate a value of at least p<0.05. Data are presented as 
mean±SEM (n=4).  
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Figure 4. Effect cabergoline on body weight and serum levels of prolactin, insulin, and triglycerides in hCGβ+ 
females. Body weight (A) and serum prolactin (B), insulin (C) and trygicerides (D) levels in 6-month-old 
cabergoline- treated transgenic females (hCGβ+cab)  after 18 hr fasting. WT, cabergoline-tretated WT 
(WTcab) and hCGβ+ females were used as controls. ANOVA, followed by Bonferroni’s post hoc test was 
conducted. Different letters indicate a value of at least p<0,05. Data are presented as mean±SEM (n=4-12). 
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Figure 5. Effect of cabergoline treatment on the glucose homeostasis in WT and hCGβ+ females.  IGTT (2 
g/kg) (A), and ITT (0,75 IU/kg) (C) in fasted 6-month-old cabergoline- treated transgenic (hCGβ+cab) 
females was performed; fasted 6-month-old WT, cabergoline-treated WT (WTcab) and hCGβ+ females were 
used as control groups. Two-way ANOVA with repeated-measures, followed by Bonferroni’s post hoc test 
was conducted. A) WT vs hCGβ+ **: p<0,01; ***: p<0,001; hCGβ+ vs hCGβ+cab ##: p<0,01; C) hCGβ+ 
vs WT, WTcab, hCGβ+cab; **: p<0,01, ***: p<0,001. The area under the curve (AUC) was analyzed for 
the different groups (B, D). ANOVA followed by Bonferroni’s post hoc test was conducted. Different letters 
indicate a value of at least p<0,05. Data are presented as mean±SEM (n=4-12).  
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Figure 6. (A) Effect of cabergoline on the pancreatic gene expression of Ins1, Ins2, Gcg and Ccnd2. The 
mRNA expression analysis of Ins1, Ins2 and Gcg from fasted 6-month-old WT, hCGβ+ and cabergoline-
treated WT (WTcab) and hCGβ+ (hCGβ+cab) pancreata was carried out by qRT-PCR. ANOVA, followed by 
Bonferroni’s post hoc test, was conducted. Different letters indicate a value of at least p< 0.05. Data are 
presented as mean mean±SEM (n=4). (B) immunolocalization of PDX1 and NKX 6.1 in pancreas. 
Representative sections from 6-month-old WT, hCGβ+ and hCGβ+cab female mice were immunostained 
with PDX1 and NKX 6.1 specific antibodies. Scale bar 100 µm.  
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